gadolinium lipid nanoparticles

Gadolinium lipid nanoparticles are nanoparticulate MRI contrast agents that incorporate gadolinium ions onto or within lipid-based carriers, such as liposomes or lipid nanoparticles[1][4][6]. Normally, gadolinium is chelated via DTPA or similar ligands bound to lipid moieties (e.g., DTPA-phosphatidylethanolamine), stabilizing the gadolinium and enhancing its relaxivity for magnetic resonance imaging[1][4][5]. These agents are explicitly designed to address limitations of conventional gadolinium agents, such as nephrotoxicity, by improving vascular retention and preferentially biliary clearance, making them potentially safer for patients with renal impairment[1]. Gadolinium lipid nanoparticles can be further engineered for dual purposes—exhibiting high relaxivity and clearance properties, and for targeted molecular imaging or theranostic delivery, including co-encapsulation of therapeutic drugs or targeting ligands[1][5][6]. Preclinical studies demonstrate their use for blood pool and vascular imaging, tumor targeting, and as platforms for molecular imaging, with potential applications in oncology, cardiovascular disease, and stroke[1][4][5][6].

Other names

Gd-LNPGd-lipid nanoparticlesGd-lipGd-DTPA-LNPDual-Gd liposomes